ProCE Banner Activity

KRYSTAL-1 Trial of Adagrasib in Patients With Previously Treated Advanced KRASG12C-Mutated NSCLC: Analysis of Registrational Phase II Cohort

Slideset Download
Conference Coverage
Adagrasib monotherapy was associated with clinical activity, intracranial response, and manageable toxicity in patients with previously treated NSCLC harboring a KRASG12C mutation.

Released: June 06, 2022

Expiration: June 05, 2023

No longer available for credit.


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from



Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.


Jazz Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen and Genmab